Approval · Notice of Compliance 16780 · 2015
AREDIA: Notice of Compliance 16780
Issued March 27, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16780
- Date
- March 27, 2015
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a rapid microbiological tes method as an alternative sterility test method for finished product release and stability
- Therapeutic class
- Bone metabolis regultor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AREDIA | Not yet assigned | — |
Medicinal ingredients
- PAMIDRONATE DISODIUM 30 MG per VIAL
- PAMIDRONATE DISODIUM 90 MG per VIAL